Confirmatory DPYD Testing in MGI Subjects

Written By Phil Jacokes

Overview

This project identified patients carrying DPYD variants based on Michigan Genomics Initiative. The results of this project was a call on the FDA to follow our European counterparts in recommending DPYD testing and genotype-based dose adjustment to ensure patients with cancer receive safe and effective FP chemotherapy.

Principal Investigator(s)

Dan Hertz, PharmD, PhD

Digital Health Innovation Support

Digital Health Innovation provided genetic data, honest broker services, and computational resources. In addition, the Model Deployment Team provided guidance to the upstream regulatory process (IRB) and connected the study team with subject matter experts within Michigan Medicine to help develop clinical return of results workflow for patients carrying DPYD.


Partnerships

College of Pharmacy 

MGI Access Committee 

Clinical Trials Support Unit (CTSU, CRAO)

MM Medical Oncologists 

MiChart Pathology

Phil Jacokes
Previous

Providing Mental Health Precision Treatment (PROMPT)